However, bevacizumab (an anti-VEGFA antibody) had limited improvement in overall survival in glioblastoma patients and was associated with higher adverse events, although it increased progression-free survivals [8–10], hence the underlying mechanisms mediated by VEGFR need to be further explored. The gene discussed is KDR; the disease is glioblastoma.